

Keith L Davis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2415760/publications.pdf>

Version: 2024-02-01

18
papers

496
citations

1162367

8
h-index

887659

17
g-index

18
all docs

18
docs citations

18
times ranked

678
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. <i>Epilepsia</i> , 2008, 49, 446-454.	2.6	196
2	Direct Economic Burden of Chronic Hepatitis C Virus in a United States Managed Care Population. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, e17-e24.	1.1	120
3	Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data. <i>Movement Disorders</i> , 2010, 25, 474-480.	2.2	71
4	Treatment patterns and characteristics of patients with migraine in Japan: A retrospective analysis of health insurance claims data. <i>Cephalalgia</i> , 2019, 39, 1518-1534.	1.8	36
5	Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. <i>Future Oncology</i> , 2021, 17, 2759-2768.	1.1	16
6	European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review. <i>Drugs - Real World Outcomes</i> , 2021, 8, 537-545.	0.7	10
7	Comorbidity Burden in Elderly Persons with Non-CML Myeloproliferative Neoplasms: Real-World Evidence From a United States Medicare Population. <i>Blood</i> , 2012, 120, 1734-1734.	0.6	10
8	Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France. <i>Advances in Hematology</i> , 2019, 2019, 1-12.	0.6	9
9	Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. <i>Future Oncology</i> , 2022, 18, 2217-2231.	1.1	7
10	Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 699-710.	0.7	5
11	Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1325-1334.	0.6	4
12	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3528-3528.	0.6	3
13	Health Care Utilization and Associated Costs in Elderly Persons with Non-CML Myeloproliferative Neoplasms: Real-World Evidence From a United States Medicare Population. <i>Blood</i> , 2012, 120, 4273-4273.	0.6	2
14	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL). <i>Blood</i> , 2021, 138, 1349-1349.	0.6	2
15	Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice. <i>Cancer Reports</i> , 0, , .	0.6	2
16	Medicare Fee-for-Service Enrollees with Acute Myelogenous Leukemia: An Analysis of Treatment Patterns and Patient Survival. <i>Blood</i> , 2011, 118, 505-505.	0.6	1
17	Survival Patterns in Patients with Non-CML Myeloproliferative Neoplasms: Evidence From a United States SEER/Medicare Population. <i>Blood</i> , 2012, 120, 428-428.	0.6	1
18	Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	1